Navigation Links
Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
Date:6/16/2008

HAYWARD, Calif., June 16 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has completed enrollment in a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides.

The randomized, double-blind study is designed to assess the drug's effect on dyslipidemia and insulin resistance, and will evaluate two different doses of MBX-8025 given over an 8-week period, both alone and in combination with Lipitor(R) (atorvastatin). The primary endpoint is the reduction in Apo B-100, the atherogenic lipoprotein in LDL (low-density lipoprotein), compared to placebo. Secondary endpoints include measurements of the effect of treatment on LDL, HDL (high-density lipoprotein), triglycerides and body weight and composition. Metabolic parameters, including glucose and insulin levels and insulin sensitivity, are also being assessed.

"America is suffering from an epidemic of obesity and its consequences, one of which is mixed dyslipidemia. Patients with this type of dyslipidemia have elevated LDL cholesterol, but also have elevated triglycerides, low HDL levels, and have a large amount of small, dense LDL particles, which are much more atherogenic," said David B. Karpf, M.D., the chief medical officer of Metabolex. "Statins do a good job of lowering LDL, but are not fully effective because they do not treat the other aspects of mixed dyslipidemia. This enrollment milestone puts us one step closer to understanding the ability of MBX-8025 to treat mixed dyslipidemia, as well as providing preliminary evidence of the drug's ability to enhance insulin sensitivity and reduce body weight -- two additional features of metabolic syndrome."

About Dyslipidemia

A growing body of research indicates that cardiac risk is affected by a number of different compounds in the blood,
'/>"/>

SOURCE Metabolex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Metabolex Initiates Phase 1 Trial of MBX-2982
2. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
3. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
4. Pharmaxis Long-Term Safety Study of Bronchitol Completes
5. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
6. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
7. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
8. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
9. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
10. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
11. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... District Court for the District of New ... the company,s case against Sandoz, Inc. regarding United Therapeutics, ... Sheridan ruled that U.S. Patent No. 6,765,117 is ... Sandoz from marketing its generic product until the expiration ...
(Date:8/29/2014)... , August 29, 2014 ... Market by Product & Services (Equipment, Reagent, Primer, ... Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, ... MarketsandMarkets, the global Oligonucleotide Synthesis Market is expected ... Million in 2014, growing at a CAGR of ...
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
(Date:9/1/2014)... is a leading review website in the world. It ... announced that GreenGeeks, Arvixe and Hostgator are the best ... http://www.greengeeks.com/cgi-bin/affiliates/clickthru.cgi?id=seohosts ) is one of the best web hosting ... of useful products for sale. On its website, customers ... , As one of the Top 10 Web Hosting ...
(Date:9/1/2014)... may be bad for your waistline. TV viewers ate ... excerpt from a Hollywood action film than those watching ... for helping Americans to gain weight because it encourages ... been on the medium and not the message. TV ... to eat more, including reading, listening to the radio ...
(Date:9/1/2014)... 1, 2014 (HealthDay News) -- You may be able to ... ones, new research suggests. The study included eight overweight ... weight-loss program meant to change how people react to different ... five overweight and obese people who weren,t in the program. ... of the study and again six months later. The scans ...
(Date:9/1/2014)... Albany, New York (PRWEB) September 01, 2014 ... specially-fitted room in a hospital for performing surgical operations. ... such as operating tables, surgical booms, operating room lights, ... rooms. According to a report by Transparency Market Research, ... market is expected to reach USD 4.5 billion by ...
(Date:9/1/2014)... HealthDay Reporter FRIDAY, Aug. 29, 2014 (HealthDay ... American aid workers successfully cured a group of monkeys infected ... The drug, ZMapp, prompted recovery in all 18 monkeys who ... five days after infection. ZMapp even cured monkeys with ... away from death, said study senior author Gary Kobinger, chief ...
Breaking Medicine News(10 mins):Health News:The Best Reseller Hosting Suppliers in August Released by Leading Review SiteTop10BestSEOHosting.com 2Health News:Research letter: Viewers ate more while watching Hollywood action flick on TV 2Health News:Train Your Brain to Choose Fruit Salad Over French Fries 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3
... Two new vitamin D studies using a sophisticated form of ... combined, have revealed new prescriptions for// possibly preventing up to ... the cases of colorectal cancer in the United States. The ... specialists at the Moores Cancer Center at University of California, ...
... older men experience the symptoms of an enlarged prostate multiple ... know is that the disease// known as BPH (benign prostatic ... but at least a pair of disorders, and that one ... — has far more serious implications. ,In a ...
... not sound like such a bad thing. But a condition ... PCOS – can present women with numerous health concerns, ranging ... risk of heart disease and diabetes. ,PCOS affects ... one of the more common hormonal abnormalities women experience during ...
... use for checking body temperature is most lethal and ... ,Mercury is a neurotoxin, meaning it attacks the ... has been linked to birth defects, learning disabilities, walking ... ,In adults, mercury poisoning leads to tremors, headaches, ...
... of launching an oral vaccine for diabetes that would ... to millions in the country// suffering from the debilitating ... Transgene Biotek Ltd is currently doing research and pre-clinical ... Institute of Chemical Technology (IICT), Hyderabad. ,"We ...
... dead pregnant woman on life support had passed the milestone ... outside the womb, giving her family new hope. The family ... was a possible name the couple had discussed before her ... have assumed an important criterion in the use and abuse ...
Cached Medicine News:Health News:Two New Studies Back Vitamin D for Cancer Prevention 2Health News:Two New Studies Back Vitamin D for Cancer Prevention 3Health News:Severe Form of “Enlarged Prostate” Disease Discover 2Health News:Condition That Causes Irregular Periods Can Lead to Fertility Problems 2Health News:Condition That Causes Irregular Periods Can Lead to Fertility Problems 3Health News:Mercury can Kill 2Health News:Mercury can Kill 3Health News:India Developing Oral Vaccine to Fight Diabetes 2Health News:Ultrasound Technology - Boon or a Bane? 2Health News:Ultrasound Technology - Boon or a Bane? 3Health News:Ultrasound Technology - Boon or a Bane? 4
...
Cobb Curettes, reverse angled, 11"....
Malis Needle Holders, bayonet, titanium. Working distance 2 1/2" (63 mm). Straight tip with width 0.6 mm....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Medicine Products: